Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gym Group bullish on growth prospects after profits jump in 2024

(Sharecast News) - Low-cost gym operator The Gym Group reported a double-digit increase in revenues and profits for 2024, bolstered by membership increases and price hikes, as it guided to 2025 earnings at the top end of analysts' forecasts. The company said that trading has remained strong over the key member recruitment months of January and February. As a result, full-year adjusted EBITDA minus normalised rent should be at the top end of the consensus range of £49.0m-50.8m.

Group revenues totalled £226.3m in 2024, up 11% on the year before, with the number of members rising 5% to 891,000 by the year-end.

The company also increased the number of gyms by 5% to 245 gyms by year-end, while the average price of its standard membership was £24.53, up 6% over the year.

"Like-for-like revenue growth of 7% reflects a combination of higher headline rates for new members, re-pricing of the existing member base, and more cost-effective promotional activity," the company said.

Group adjusted EBITDA minus normalised rent totalled £47.7m in 2024, up 24% over the year before. Free cash flow rose to £37.5m, up 39% from 2023.

With plans to open a further 14 to 16 new sites in 2025, The Gym Group said it remains on track to open around 50 sites over three years, funded from free cash flow.

"We believe there is still more benefit to come from the Next Chapter growth plan, giving us the confidence to increase guidance again to the top end of the recently revised analyst forecast range for FY25," said chief executive Will Orr.

Shares were up nearly 7% at 143.8p by 0816 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.